Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Biomarkers of Inflammation and Neuronal and Glial Injury in Neurosarcoidosis: A Prospective, Observational Pilot Study
Autoimmune Neurology
P8 - Poster Session 8 (5:30 PM-6:30 PM)
14-001
Markers of neuronal and glial injury have been adapted for monitoring disease activity and injury in individuals with neurodegenerative and neuroinflammatory disorders. There are currently no biomarkers that inform on disease activity, prognosis, and treatment in NS.

Compare the concentrations of plasma-based neuronal and glial biomarkers obtained from patients with Neurosarcoidosis (NS) to non-inflammatory controls.

This is a prospective, observational study to study biomarkers of inflammation and neuronal injury with associated clinical outcome measures in patients with NS. Plasma concentrations of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, Ubiquitin carboxy-terminal hydrolase L1 (UCHL-1) in patients with NS (Possible, probable, and definite) and healthy controls (HC) using Quanterix SIMOA were evaluated. Ongoing collection and statistical analysis will aim to report longitudinal analysis correlated with clinical progression. 
To date, plasma from 16 NS patients  has been collected; age(x ¯=55.8 SD=8.3) percent female(50.0%). Cross-sectional analysis of 8 plasma based samples from patients with NS shows a mean plasma concentrations of NfL, GFAP, and UCH-L1 were elevated in  NS patients compared to HCs of similar sex and age distribution (n=8 NS; 8 HC): NFL (26.4 v. 4.3 pg/ml, p = 0.0030 ), GFAP (137.4 v. 32.5 pg/ml, p < 0.0002 ), UCH-L1 (26.1 v. 5.0 pg/mL, p = 0.0030). Plasma tau levels were not different (1.9 v. 2.9 pg/mL, p = 0.1304). In NS patients CSF concentrations were as follows: NfL (x ¯=4252.8 pg/ml; SD=5625.1), GFAP (x ¯=10289.9 pg/ml; SD=4125.6), UCH-L1 (x ¯=2667.5 pg/ml; SD=1425.3), tau (x ¯=52.8 pg/ml; SD=22.9). Ongoing longitudinal analysis correlating to clinical outcome measures include modified Rankin Scale and Expanded Disability Status Scale.
Preliminary results show plasma NfL, GFAP, and UCHL-1 levels are elevated in NS at the time of their disease onset. Additional inflammatory markers with cytokine analysis and longitudinal studies to correlate biomarkers for disease progression are ongoing.
Authors/Disclosures
Paul D. Crane, MD (University of Colorado)
PRESENTER
Dr. Crane has nothing to disclose.
Christopher S. Mizenko (University of Colorado) Mr. Mizenko has nothing to disclose.
Tyler L. Borko, BA, EMT-IV (University of Colorado) Mr. Borko has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Amanda L. Piquet, MD, FAAN (University of Colorado) The institution of Dr. Piquet has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. The institution of Dr. Piquet has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. The institution of Dr. Piquet has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. The institution of Dr. Piquet has received personal compensation in the range of $0-$499 for serving as a Consultant for EMD Serono. Dr. Piquet has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Piquet has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Piquet has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Piquet has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Sands Anderson PC. Dr. Piquet has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Joe Jones Law Firm. The institution of Dr. Piquet has received research support from Rocky Mountain MS Center. The institution of Dr. Piquet has received research support from Novartis. The institution of Dr. Piquet has received research support from Abbvie. The institution of Dr. Piquet has received research support from Roche/Genentech. The institution of Dr. Piquet has received research support from NYU. The institution of Dr. Piquet has received research support from Anokion. The institution of Dr. Piquet has received research support from UCB . The institution of Dr. Piquet has received research support from Foundation for Sarcoidosis. Dr. Piquet has received publishing royalties from a publication relating to health care. Dr. Piquet has received publishing royalties from a publication relating to health care. Dr. Piquet has received personal compensation in the range of $10,000-$49,999 for serving as a Litigative Consultant with US-Dept HHS/DICP. Dr. Piquet has a non-compensated relationship as a Medical Advisory Board Member with Autoimmune Encephalitis Alliance (AEA) that is relevant to AAN interests or activities. Dr. Piquet has a non-compensated relationship as a Medical Advisory Board Member with Stiff Person Syndrome Research Foundation (SPSRF) that is relevant to AAN interests or activities.